Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Mebanks Divests Guangzhou Specialty Pharmacy Subsidiary to DaShenLin for $7.75 Million to Focus on Higher-Margin Health Insurance and Management Businesses

Fineline Cube Apr 23, 2026
Company Deals

AbbVie Announces $1.4 Billion Advanced Manufacturing Campus in North Carolina to Support Immunology, Neuroscience, and Oncology Portfolio

Fineline Cube Apr 23, 2026
Company Deals Digital

Merck & Co. Announces $1 Billion Strategic Partnership with Google Cloud to Deploy Enterprise-Wide Agentic AI Platform

Fineline Cube Apr 23, 2026
Company Deals

Boji Medical Sells Fluconazole Ear Drops Technology to Chengdu Pusch for $2M

Fineline Cube Apr 22, 2026
Company Deals

Novabio Therapeutics and OBiO Tech Strengthen Partnership to Advance Treg Cell Therapies for Neurodegenerative Diseases

Fineline Cube Apr 22, 2026
Policy / Regulatory

NMPA Suspends Colchicine API Imports from Indian Manufacturers Alkaloids Bioactives and Alchem International Over Change Management Violations

Fineline Cube Apr 23, 2026
Company Drug

Transcenta Presents Promising Pre-clinical Data for Proprietary LIV1 Antibody-Drug Conjugate at AACR 2026

Fineline Cube Apr 23, 2026
Company Drug

Simcere Pharmaceutical Withdraws NDA for Rademikibart in Atopic Dermatitis, Plans Resubmission Later This Month

Fineline Cube Apr 23, 2026
Company Deals

CellOrigin and Qilu Partner on Global CAR-iMAC Cancer Therapy Development

Fineline Cube Sep 6, 2022

CellOrigin Biotech (Hangzhou) Co., Ltd, a China-based biotech firm specializing in allogeneic cell therapies, has...

Company Deals

Bio-Heart Plans STAR Board IPO After Hong Kong Debut to Advance Cardiovascular Therapies

Fineline Cube Sep 6, 2022

Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185), a leading Chinese innovator in interventional cardiovascular...

Company Deals

Fosun Pharma’s Controlling Shareholder to Sell 3% Stake for USD 461 Million

Fineline Cube Sep 6, 2022

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) announced that its controlling shareholder, Shanghai Fosun...

Company Drug

SciClone Pharmaceuticals Doses First Patient in RRx-001 Phase III Study for SCLC

Fineline Cube Sep 6, 2022

China-based SciClone Pharmaceuticals Inc. (Nasdaq: SCLN) announced that the first patient has been dosed in...

Company Medical Device

Hotgen Biotech Receives UK Approvals for Monkeypox and COVID-19 Antigen Detection Kits

Fineline Cube Sep 6, 2022

Shanghai-based Hotgen Biotech Co., Ltd (SHA: 688068) has announced significant regulatory milestones in the United...

Company Drug

Zelgen Biopharm’s Donafenib Shows Promise in Phase III Study for RAIR-DTC

Fineline Cube Sep 6, 2022

China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced positive results from the Phase III...

R&D

BGI’s Stereo-seq Tech Maps Axolotl Brain Regeneration in World-First Study

Fineline Cube Sep 5, 2022

China’s genomics giant BGI has revealed a landmark study using its proprietary Stereo-seq sequencing technology...

Company Drug

Yingli Pharma Doses First Patient in Linperlisib Phase II Trial for PTCL

Fineline Cube Sep 5, 2022

US-based Yingli Pharma, which targets the China and US drug markets, has dosed the first...

Company Deals

Junshi Biosciences Plans USD 572M Private Placement to Fund Drug R&D and Expansion

Fineline Cube Sep 5, 2022

China’s Shanghai Junshi Biosciences Co., Ltd (SHA: 688180, HKG: 1877) announced plans to raise up...

Company Drug

CanSino, Livzon Win China EUAs for COVID-19 Booster Vaccines

Fineline Cube Sep 5, 2022

China-based vaccine makers CanSino Biologics (HKG: 6185) and Livzon Pharmaceutical Group Inc. (HKG: 1513) have...

Company Deals Digital

AWS Partners with Zhongshan to Launch Smart Manufacturing and Biomedical Digital Center

Fineline Cube Sep 5, 2022

Amazon Web Services (AWS) and Zhongshan’s Bureau of Commerce announced a partnership at the China...

Company Deals

BoomRay Pharmaceuticals Raises USD 43M in Series A for RDC Pipeline Expansion

Fineline Cube Sep 5, 2022

China’s BoomRay Pharmaceuticals, a specialist in radionuclide drug conjugates (RDCs), reportedly raised nearly RMB 300...

Company Drug

Zelgen Biopharmaceuticals’ Jacktinib Wins FDA Approval for Severe Alopecia Areata

Fineline Cube Sep 5, 2022

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) secured U.S. FDA approval to launch a clinical...

Company Drug

Jacobio Pharmaceuticals Doses First Patient in JAB-BX102 Phase I/IIa Trial for CD73-Targeted Cancer Therapy

Fineline Cube Sep 5, 2022

China’s Jacobio Pharmaceuticals Group Co., Ltd (HKG: 1167) announced the first patient dosed in a...

Company Deals Drug

Northeast Pharma Licenses MedAbome’s MAb11-22.1 for ADC and CAR-T Development

Fineline Cube Sep 5, 2022

China’s Northeast Pharmaceutical Co., Ltd (SHE: 000597) has signed a licensing agreement with U.S.-based MedAbome...

Company Drug

Alphamab Oncology Highlights KN046, KN026 Advances at ESMO 2022

Fineline Cube Sep 5, 2022

China’s Alphamab Oncology (HKG: 9966) will present updated clinical data for its bispecific antibody candidates...

Company Drug

AstraZeneca’s Farxiga Wins China Approval for Chronic Kidney Disease

Fineline Cube Sep 5, 2022

UK pharma giant AstraZeneca (AZ, NASDAQ: AZN) announced a new approval for Farxiga (dapagliflozin), its...

Company Drug

Innovent Biologics Doses First Patient in Higher-Dose Mazdutide Obesity Trial

Fineline Cube Sep 5, 2022

China’s Innovent Biologics, Inc. (HKG: 1801) announced that the first participant has been dosed in...

Company Drug

Shanghai Pharma’s CD20 Antibody Advances to Primary Nephropathy Trial After NMPA Approval

Fineline Cube Sep 5, 2022

China’s Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) has received approval from the National Medical Products...

Company Drug

Walvax Biotech Wins NMPA Approval for mRNA and Recombinant COVID-19 Vaccines

Fineline Cube Sep 2, 2022

China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has received clinical trial approvals from the National...

Posts pagination

1 … 618 619 620 … 656

Recent updates

  • Roche Q1 Sales Rise 6% Driven by Innovative Medicines as China Expansion and Diagnostics Recovery Offset Currency Headwinds
  • Transcenta Presents Promising Pre-clinical Data for Proprietary LIV1 Antibody-Drug Conjugate at AACR 2026
  • Simcere Pharmaceutical Withdraws NDA for Rademikibart in Atopic Dermatitis, Plans Resubmission Later This Month
  • Hengrui Pharmaceuticals Reports Strong Q1 2026 Results with 12.98% Revenue Growth and Multiple New Drug Approvals
  • Mebanks Divests Guangzhou Specialty Pharmacy Subsidiary to DaShenLin for $7.75 Million to Focus on Higher-Margin Health Insurance and Management Businesses
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Roche Q1 Sales Rise 6% Driven by Innovative Medicines as China Expansion and Diagnostics Recovery Offset Currency Headwinds

Company Drug

Transcenta Presents Promising Pre-clinical Data for Proprietary LIV1 Antibody-Drug Conjugate at AACR 2026

Company Drug

Simcere Pharmaceutical Withdraws NDA for Rademikibart in Atopic Dermatitis, Plans Resubmission Later This Month

Company

Hengrui Pharmaceuticals Reports Strong Q1 2026 Results with 12.98% Revenue Growth and Multiple New Drug Approvals

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.